Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome

Journal of Chronic Fatigue Syndrome

Volumn 5, Issue 3-4, 1999, Pages 223-242

  Suhadolnik, Robert J ^a   Peterson, Daniel L ^b   Cheney, Paul R ^c   Horvath, Susan E ^a   Reichenbach, Nancy L ^a   O'Brien, Karen ^b   Lombardi, Vincent ^a   Welsch, Suzanne ^d   Furr, Elizabeth G ^c   Charubala, Ramamurthy ^e   Pfleiderer, Wolfgang ^e  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sierra Internal Medicine Associates   (United States)

^c Cheney Clinic   (United States)

^d Sierra Nevada College   (United States)

^e UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

2 5A; Antiviral defense pathway; Chronic fatigue syndrome (CFS); Interferon; Peripheral blood mononuclear cells; RNase L

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; INTERFERON; RIBONUCLEASE III;

ANTIVIRAL ACTIVITY; ARTICLE; CELL GROWTH; CHRONIC FATIGUE SYNDROME; DEPRESSION; DEREGULATION; ENZYME ACTIVATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MAMMAL; MOLECULAR WEIGHT; RATING SCALE;

EID: 6544233880     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v05n03_19     Document Type: Article

References (36)

1. Holmes GP, Kaplan JE, Glantz, NM, et al.: Chronic Fatigue Syndrome: A Working Case Definition. Ann Intern Med 1988; 108: 387-389.
2. Fukuda K, Straus SE, Hickie I, et al.: International Chronic Fatigue Syndrome Study Group, The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. Ann Intern Med 1994; 121: 953-959.
3. Reyes M, Nisenbaum R, Stewart G, et al.: Update: Wichita Population-Based Study of Fatiguing Illness, Fourth International AACFS Research and Clinical Conference on CFIDS, Cambridge, Massachusetts, October 10-12, 1998.
4. Bates D, Buchwald D, Lee J, et al.: Clinical Laboratory Test Findings in Patients with Chronic Fatigue Syndrome. Arch Intern Med 1993; 155: 97-103.
5. Chao CC, Janoff EN, Hu SX, et al.: Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome. Cytokine 1991; 3: 292-298.
6. McGregor NR, Dunstan RH, Zerbes M, et al.: Preliminary Determination of a Molecular Basis to Chronic Fatigue Syndrome. Biochem Molec Med 1996; 57: 73-80.
7. Levy JA: Viral Studies of Chronic Fatigue Syndrome. Clin Infect Dis 1994; 18: S117-S120.
8. Straus S, Fritz S, Dale J, et al.: Lymphocyte Phenotype and Function in the Chronic Fatigue Syndrome. J Clin Immunol 1993; 13: 30-40.
9. Demitrack M, Dale J, Straus S, et al.: Evidence for Impaired Activation of the Hypothalamic-Pituitary-Adrenal Axis in Patients with Chronic Fatigue Syndrome. J Clin Endocrinol Metab 1991; 73: 1224-1234.
10. Caliguiri M, Murray C, Buchwald D, et al.: Phenotypic and Functional Deficiency of Natural Killer Cells in Patients with Chronic Fatigue Syndrome. J Immunol 1987; 139: 3306-3313.
11. Klimas NG, Salvato FR, Morgan R, et al.: Immunologic Abnormalities in Chronic Fatigue Syndrome. J Clin Microbiol 1990; 28: 1403-1410.
12. Komaroff AL, and Buchwald DS: Chronic Fatigue Syndrome: An Update. Annu Rev Med 1998; 49: 1-13.
13. Lengyel P: Biochemistry of Interferons and Their Actions. Annu Review Biochem 1982; 51: 251-282.
14. Sen GC, Ransohoff RM: Interferon-Induced Antiviral Actions and Their Regulation. Adv Virus Res 1993; 42: 57-102.
15. Player MR, Torrence PF: The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation. Pharmacol Ther 1998; 78: 55-113.
16. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al.: Upregulation of the 2-5A Synthetase/RNase L Antiviral Pathway Associated with Chronic Fatigue Syndrome. Clin Infect Dis 1994; 18: S96-S104.
17. 12U) in Chronic Fatigue Syndrome. In Vivo 1994; 8: 599-604.
18. Suhadolnik RJ, Peterson DL, O'Brien K, et al.: Biochemical Evidence for a Novel Low Molecular Weight 2-5A-Dependent RNase L in Chronic Fatigue Syndrome. J Interferon & Cytokine Res 1997; 17: 377-385.
19. Morag A, Tobi M, Ravid Z, et al.: Increased (2′-5′)-Oligo-A Synthetase Activity in Patients with Prolonged Illness Associated with Serological Evidence of Persistent Epstein-Barr Virus Infection. Lancet 1982; 744.
20. Bisbal C, Martinand C, Silhol M, et al.: Cloning and Characterization of a RNase L Inhibitor, A New Component of the Interferon-Regulated 2-5A Pathway. J Biol Chem 1995; 270: 13308-13317.
21. Wells V, Mallucci L: Expression of the 2-5A System During the Cell Cycle. Exp Cell Res 1985; 159: 27-36.
22. Bisbal C, Campine I, DeBecker P, et al.: A 2-5A Binding Polypeptide of 37 kDa as a Potential Biochemical Marker for Chronic Fatigue Syndrome. International Society for Interferon and Cytokine Research, San Diego, CA, October 19-24, 1997.
23. DeMeirleir K, Campine I, DeBecker P, et al.: RNase L Dysfunction Disorder (R.E.D.D.) in CFS, Fourth International AACFS Research and Clinical Conference on CFIDS, Cambridge, Massachusetts, October 10-12, 1998.
24. Solomon V, Leckert SH, and Goldberg AL.: The N-End Rule Pathway Catalyzes a Major Fraction of the Protein Degradation in Skeletal Muscle. J Biol Chem 1998; 273: 25216-25222.
25. Borish L, Schmaling K, DiClementi JD, et al.: Chronic Fatigue Syndrome: Identification of Distinct Subgroups on the Basis of Allergy and Psychologic Variables. J Allergy & Clin Immunol 1998; 102: 222-230.
26. Patarca R, Klimas N, Sandler D, et al.: Interindividual Immune Status Variation Patterns in Patients with Chronic Fatigue Syndrome: Association with Gender and the Tumor Necrosis Factor System. J Chronic Fatigue Syndrome 1996; 2: 13-39.
27. Chao CC, Janoff EN, Hu SX, et al.: Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome. Cytokine 1991; 3: 292-298.
28. Chapekar MS, Glazer RI: The Synergistic Cytocidal Effect Produced by Immune Interferon and Tumor Necrosis Factor in HT-29 Cells Is Associated with Inhibition of rRNA Processing and (2,5)-Oligo(A) Activation of RNase L. Biochem Biophys Res Commun 1988; 151: 1180-1187.
29. Keppler-Hafkemeyer A, Brinkmann U, Pastan I: Role of Caspases in Immunotoxin-Induced Apoptosis of Cancer Cells. Biochemistry 1998; 37: 16934-16942.
30. Dong D, Silverman RH: A Bipartite Model of 2-5A-Dependent RNase L. J Biol Chem 1997; 272: 22236-22242.
31. Horvath SE, Peterson DL, Suhadolnik RJ: Characterization of RNase L Dysfunction in Peripheral Blood Mononuclear Cell Extracts from Patients with Chronic Fatigue Syndrome, Fourth International AACFS Research and Clinical Conference on CFIDS, Cambridge, Massachusetts, October 10-12, 1998.
32. Silverman RH, Jung DD, Nolan-Sorden NL, et al.: Purification and Analysis of Murine 2-5A-Dependent RNase. J Biol Chem 1988; 263: 76336-7342.
33. Marie I, Hovanessian AG: The 69-kDa 2-5A Synthetase Is Composed of Two Homologous and Adjacent Functional Domains. J Biol Chem 1992; 267: 9939-9942.
34. Zhou A, Hassel BA, Silverman RH: Expression Cloning of 2-5A-Dependent RNase. A Uniquely Regulated Mediator of Interferon Action. Cell 1993; 72: 753-765.
35. Borowsky B, Hoffman BJ: Analysis of a Gene Encoding Two Glycine Transporter Variants Reveals Alternative Promoter Usage and a Novel Gene Structure. J Biol Chem 1998; 273: 29077-29085.
36. Levine PH, Whiteside TL, Friberg D, et al.: Dysfunction of Natural Killer Activity in a Family with Chronic Fatigue Syndrome. Clin Immunol Immunopathol 1998; 88: 96-104.